Marrone Bio Innovations Inc (NASDAQ:MBII) traded up 8.5% during mid-day trading on Tuesday . The company traded as high as $1.44 and last traded at $1.41, 102,220 shares were traded during trading. A decline of 13% from the average session volume of 118,104 shares. The stock had previously closed at $1.30.
A number of equities analysts recently issued reports on the company. National Securities reissued a “buy” rating and set a $2.50 price target on shares of Marrone Bio Innovations in a report on Friday. HC Wainwright reissued a “buy” rating and set a $2.50 price target on shares of Marrone Bio Innovations in a report on Monday. Finally, Aegis assumed coverage on Marrone Bio Innovations in a report on Wednesday, July 24th. They set a “buy” rating and a $2.00 price target on the stock.
The company has a current ratio of 1.94, a quick ratio of 1.47 and a debt-to-equity ratio of 2.47. The company has a fifty day moving average price of $1.40. The company has a market capitalization of $145.52 million, a PE ratio of -6.71 and a beta of -0.15.
Marrone Bio Innovations (NASDAQ:MBII) last released its quarterly earnings results on Thursday, August 8th. The basic materials company reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.02). Marrone Bio Innovations had a negative return on equity of 157.42% and a negative net margin of 86.09%. The company had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $9.01 million. On average, sell-side analysts predict that Marrone Bio Innovations Inc will post -0.16 earnings per share for the current year.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. boosted its holdings in Marrone Bio Innovations by 0.5% in the 4th quarter. BlackRock Inc. now owns 2,800,519 shares of the basic materials company’s stock valued at $4,117,000 after purchasing an additional 14,014 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Marrone Bio Innovations by 5.8% in the 4th quarter. Geode Capital Management LLC now owns 443,611 shares of the basic materials company’s stock valued at $652,000 after purchasing an additional 24,460 shares in the last quarter. Spark Investment Management LLC boosted its holdings in Marrone Bio Innovations by 47.5% in the 1st quarter. Spark Investment Management LLC now owns 95,000 shares of the basic materials company’s stock valued at $145,000 after purchasing an additional 30,600 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Marrone Bio Innovations in the 1st quarter valued at approximately $74,000. 42.01% of the stock is currently owned by institutional investors.
About Marrone Bio Innovations (NASDAQ:MBII)
Marrone Bio Innovations, Inc provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation.
Recommended Story: Why are analyst ratings important in trading stocks?
Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.